The metabolic syndrome and dyslipidemia in primary and secondary prevention: examining the implications of recent trials

Bibliography

• Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287, 356-359 (2002).
   Google Scholar
• Sakkinen PA, Wahl P, Cushman M et al. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am. J. Epidemiol. 152, 897-907 (2000).
   Google Scholar
• Howard G, Bergman R, Wagenknecht LE et al. Ability of alternative indices of insulin sensitivity to predict cardiovascular risk: comparison with the ‘minimal model.’ Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Ann. Epidemiol. 8, 358-369 (1998).
   Google Scholar
• Grundy SM. Hypertriglyceridiema, atherogenic dyslipidemia, and the metabolic syndrome. Am. J. Cardiol. 81, 18B-25B (1998).
   Google Scholar
• Freedman JE. Oxidative stress and platelets. Arterioscler. Thromb. Vasc. Biol. 28, S11-S16 (2008).
   Google Scholar
• Ridker PM. On evolutionary biology, inflammation, infection, and the causes of atherosclerosis. Circulation 105, 2-4 (2002).
   Google Scholar
• Munzel T, Sinning C, Post F, Warnholtz A, Schulz E. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann. Med. 40, 180-196 (2008).
   Google Scholar
• Von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis.Role of cholesterol efflux and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 21, 13-27 (2001).
   Google Scholar
• De Pergola G, Pannacciulli N. Coagulation and fibrinolysis abnormalities in obesity. J. Endocrinol. Invest. 25, 899-904 (2002).
   Google Scholar
• Sakkinen PA, Wahl P, Cushman M et al. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am. J. Epidemiol. 152, 897-907 (2000).
   Google Scholar
• Ansell BJ, Navab M, Hama S et al.Inflammatory/anti-inflammatory properties ofhigh-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108, 2751-2756 (2003).
   Google Scholar
• Addresses the effect of statin treatment on lipoprotein dynamics while paying particularattention to both the anti-inflammatory and proinflammatory nature of HDL-C.
   Google Scholar
• Navab M, Yu R, Gharavi N et al. Highdensity lipoprotein: antioxidant andanti-inflammatory properties. Curr. Atheroscler. Reports 9, 244-288 (2007).
   Google Scholar
• Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteinsinhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 15(11), 1987-1994 (1995).
   Google Scholar
• Navab M, Ananthramaiah GM, Reddy ST et al. The oxidation hypothesis of atherogenesis: the role of oxidizedphospholipids and HDL. J.Lipid Res. 45, 993-1007 (2004).
   Google Scholar
• Oxidation of phospholipids is seemingly the cornerstone of differences between anti- andpro-inflammatory HDL.
   Google Scholar
• Fogelman AM. When good cholesterol goes bad. Nat. Med. 10(9), 902-903 (2004).
   Google Scholar
• Esposito K, Marfella R, Ciotola M et al.Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolicsyndrome. JAMA 292, 1440-1446 (2004).
   Google Scholar
• Bo S, Ciccone G, Baldi C et al. Effectivenessof a lifestyle intervention on metabolic syndrome: a randomized clinical trial. J. Gen. Intern. Med. 22(12), 1695-1703 (2007).
   Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The ThirdReport of The National Cholesterol Education Program (NCEP) Expert Panel onDetection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285(19),2486-2497 (2001).
   Google Scholar
• Wong ND, Pio JR, Franklin SS et al.Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am. J. Cardiol. 91,1421-1426 (2003).
   Google Scholar
• Vitale C, Mercuro G, Cornoldi A et al. Metformin improves endothelial function in patients with metabolic syndrome. J. Intern. Med. 258(3), 250 (2005).
   Google Scholar
• Pearson TA, Blair SN, Daniels SR et al. AHAguidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 106(3), 388-391 (2002).
   Google Scholar
• Athyros VG, Mikhalidis DP, Liberopoulos EN et al. Effect of statin treatment on renalfunction and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREekAtorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol. Dialysis Transplant. 22, 118-127 (2007).
   Google Scholar
• Athyros VG, Papageorgiou AA, Symeonidis AN et al.; GREACE Study Collaborative Group. Early benefit from structured care with atorvastatin in patients with coronaryheart disease and diabetes mellitus. Angiology 54, 679-690 (2003).
   Google Scholar
• Charlton-Menys V, Betteridge DJ, Colhoun H et al. Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, andapolipoprotein B in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Clin. Chem. 55, 473-480 (2009).
   Google Scholar
• Important multicenter randomized placebo-controlled trial to determine hard outcomes of atorvastatin 10 mg versus placebo in patients with Type 2 diabetes and at least one additional cardiovascular risk factor.
   Google Scholar
• Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin in the primary prevention ofcardiovascular disease among patients withlow levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 108, 2292-2297 (2003).
   Google Scholar
• Ridker PM. The JUPITER trial: results,controversies, and implications for prevention.Circ. Cardiovasc. Qual. Outcomes 2, 279-285(2009).
   Google Scholar
• Ford ES, Capewell S. Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: concealed leveling of mortality rates. J. Am. Coll. Cardiol. 50, 2128-2132 (2007).
   Google Scholar
• Fruchart JC, Sacks F, Hermans MP et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am. J. Cardiol. 102, 1-34 (2008).
   Google Scholar
• Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, Shear C; TNT Steering Committee Members and Investigators. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am. J. Cardiol. 93(2), 154-158 (2004).
   Google Scholar
• Nesto RW. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in Type 2 diabetes mellitus and the metabolic syndrome. Am. J. Cardiovasc. Drugs 5, 379-387 (2005).
   Google Scholar
• Rubins HB, Robins SJ, Collins D et al. Gefibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N. Engl. J. Med. 341, 410-418 (1999).
   Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ et al. High density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79, 8-15 (1989).
   Google Scholar
• Robins SJ, Collins D, Wittes JT. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial. JAMA 285, 1585-1591 (2001).
   Google Scholar
• Zhao XQ, Krasuski R, Baer J et al. Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS). Am. J. Cardiol. 104(11), 1457-1464 (2009).
   Google Scholar
• Singh IM, Shishehbor MH, Ansell BJ. High density lipoprotein as a therapeutic target: a systematic review. JAMA 298, 786-798 (2007).
   Google Scholar
• Tziomalos K, Athyros VG. Fenofibrate: a novel formulation in the treatment of lipid disorders: a review. Int. J. Nanomed. 1, 129-147 (2006).
   Google Scholar
• Rosenson RS, Wolff DA, Huskin AL et al. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 30, 1945-1951 (2007).
   Google Scholar
• Koskinen P, Mänttäri M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 15(7), 820-25 (1992).
   Google Scholar
• Zambon A, Brown BG, Deeb SS et al. Genetics of apolipoprotein B and apolipoprotein A1 and premature coronay artery disease. J. Intern. Med. 259(5), 473-480 (2006).
   Google Scholar
• Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes (the FIELD study): randomised controlled trial. Lancet 366, 1849-1861 (2005)
   Google Scholar
• Double-blind placebo-controlled trial of prevention of coronary heart disease in people with Type 2 diabetes. Its wide entry criteria allow the results to be generalized to a population of typical patients with diabetes consulting general practitioners
   Google Scholar
• Steinmetz A. Lipid lowering therapy in patients with Type 2 diabetes: the case for early intervention. Diabetes Metab. Res. Rev. 24, 286-293 (2008).
   Google Scholar
• Ginsberg HN, Elam MB, Lovato LC et al. Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med. 362(17), 1563-1574 (2010)
   Google Scholar
• Well-written recent paper on combination therapy specifically in a sample population with Type 2 diabetes.
   Google Scholar
• The ACCORD Study Group. Effects of intensive blood-pressure control in Type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575-1585 (2010).
   Google Scholar
• Duffy D, Rader DJ. Update on strategies to increase HDL quantity and function. Nat. Rev. Cardiol. 6, 455-463 (2009).
   Google Scholar
• Zhang LH, Kamanna VS, Zhang MC et al. Niacin inhibits surface expression of ATP synthase b chain in HepG2 cells: implications for raising HDL. J. Lipid Res. 49(6), 1195-1201 (2008).
   Google Scholar
• Carlson LA. Nicotinic acid: the broadspectrum lipid drug. A 50th anniversary review. J. Intern. Med. 258, 94-114 (2005).
   Google Scholar
• Paternostro G, Camici PG, Lammerstma AA et al. Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. A study with positron emission tomography. J. Clin. Invest. 98, 2094-2099 (1996).
   Google Scholar
• Dresner A, Laurent D, Marcucci M et al. Effects of free fatty acids on glucose transport and IRS-1 associated phosphatidylinositol 3-kinase activity. J. Clin. Invest. 103, 253-259 (1999).
   Google Scholar
• Grundy SM. Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance. Clin. Cornerstone 8(Suppl. 1), S21-S27 (2006).
   Google Scholar
• Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110, 3512-3517 (2004).
   Google Scholar
• Hoffstedt J, Wahrenberg H, Thorne A et al. The metabolic syndrome is related to beta 3-adrenoceptor sensitivity in visceral adipose tissue. Diabetologia 39, 838-844 (1996).
   Google Scholar
• Niesor EJ, Magg C, Ogawa N et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport. J. Lipid Res. 51(12), 3443-3454 (2010).
   Google Scholar
• Lagos KG, Filippatos TD, Tsimihodimos V et al. Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lipids 44(1), 9-16 (2009).
   Google Scholar
• Boden WE, Probstfield JL, Anderson T et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365, 2255-2267 (2011).
   Google Scholar
• Ismail-Beigi F, Craven T, Banerji MA et al.; ACCORD trial group. Effect of intensive treatment of hyperglycemia on microvascular outcomes in Type 2 diabetes: an analysis of ACCORD randomized trial. Lancet 376, 419-430 (2010).
   Google Scholar
• AIM-HIGH Investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH). Am. Heart J. 161(3), 471-477.e2 (2011).
   Google Scholar
• Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 37, 1595-1607 (1988).
   Google Scholar
• Athyros V, Tziomalos K, Karagiannis A et al. Dyslipidemia of obesity, metabolic syndrome and Type 2 diabetes: the case for residual risk reduction after statin treatment. Open Cardiovasc. Med. J. 5, 24-34 (2011).
   Google Scholar
• Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260, 1917-1921 (1988).
   Google Scholar
• Tsimihodimos V, Gazi I, Kostara C et al. Lipoproteins and triacylglycerol are predictors of small, dense LDL particles. Lipids 42, 403-409 (2007).
   Google Scholar
• Plump AS, Masucci-Magoulas L, Bruce C, Bisgaier CL, Breslow JL, Tall AR. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler. Thromb. Vasc. Biol. 19, 1105-1110 (1999).
   Google Scholar
• Nielsen LB. Transfer of low density lipoprotein into the arterial wall and risk of atherosclerosis. Atherosclerosis 123, 1-15 (1996).
   Google Scholar
• Anber V, Griffin BA, McConnell M, Packard CJ, Shepherd J. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 124, 261-271 (1996).
   Google Scholar
• Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am. J. Med. 94, 350-356 (1993).
   Google Scholar
• Barter PJ, Caulfield M, Eriksson M et al.; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357(21), 2109-2122 (2007).
   Google Scholar
• Morton RE. Cholesterol ester transfer protein and its plasma regulator: lipid transfer inhibitor protein. Curr. Opin. Lipidol. 10, 321-327 (1999).
   Google Scholar
• Plump AS, Bruce C, Bisgaier CL, Breslow JL, Tall AR. Increased atherosclerosis in ApoE and LDL receptor knock-out mice as a result of human cholesterol ester transfer protein transgene expression. Arterioscler. Thromb. Vasc. Biol. 19(4), 1105-1110 (1999).
   Google Scholar
• Hayek T, Masucci-Magoulas L, Jianx X et al. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesterol ester transfer protein transgene. J. Clin. Invest. 96(4), 2071-2074 (1995).
   Google Scholar
• Matsuura F, Wang N, Chen W, Jiang XC, Tall AR. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an ApoE- and ABCG1-dependent pathway. J. Clin. Invest. 116, 1435-1442 (2006).
   Google Scholar
• Yvan-Charvet L, Matsuura F, Wang N et al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler. Thromb. Vasc. Biol. 27(5), 1132-1138 (2007).
   Google Scholar
• Forrest MJ, Bloomfield D, Briscoe RJ et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br. J. Pharmacol. 154(7), 1465-1473 (2008).
   Google Scholar
• Bloomfield D, Carlson GL, Sapre A et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am. Heart J. 157(2) 352-360 (2009).
   Google Scholar
• Recent paper on CETP both as monotherapy and when given with statins.
   Google Scholar
• Krishna R, Anderson MS, Bergman AJ et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind randomized placebo-controlled Phase I studies. Lancet 370(9603), 1907-1914 (2007).
   Google Scholar
• Schwartz GG, Olsson AG, Ballantyne CM et al. Rationale and design of the dal- OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am. Heart J. 158(6), 896-901 (2009).
   Google Scholar
• Luscher TF et al. dal-VESSEL: efficacy and safety of dalcetrapib in patients with or at risk of coronary heart disease. Presented at: European Society of Cardiology Congress 2011. Paris, France, 28 August 2011.
   Google Scholar
• Fayad ZA, Mani V, Woodward M et al.; dal-PLAQUE Investigators. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 378, 1547-1559 (2011).
   Google Scholar
• Rader DJ. Regulation of reverse cholesterol transport and clinical implications. Am. J. Cardiol. 92(4A), 42J-49J (2003).
   Google Scholar
• Navab M, Berliner JA, Subbanagounder G et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler. Thromb. Vasc. Biol. 21, 481-488 (2001).
   Google Scholar
• Detailed dive into the relevance of oxidative stress on what has traditionally been referred to as ‘good’ cholesterol.
   Google Scholar
• Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr. Opin. Cardiol. 21, 322-328 (2006).
   Google Scholar
• Plump A, Scott C, Breslow J. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl Acad. Sci. USA 91, 9607-9611 (1994).
   Google Scholar
• Tangirala RK, Tsukamoto K, Chun SH et al. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 68(100), 1816-1822 (1999).
   Google Scholar
• Van Lenten BJ, Hama SY, de Beer FC et al. Anti-inflammatory HDL becomes proinflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest. 96, 2758-2767 (1995).
   Google Scholar
• Gowri MS, Van der Westhuyzen DR, Bridges SR, Anderson JW. Decreased protection by HDL from poorly controlled Type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. Arterioscl. Thromb. Vasc. Biol. 19, 2226-2233 (1999).
   Google Scholar
• Remaley AT, Thomas F, Stonik JA et al. Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1- independent pathway. J. Lipid Res. 44, 828-836 (2003).
   Google Scholar
• Zhang YZ, Zanotti I, Reilly MP et al. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation 108, 661-663 (2003).
   Google Scholar
• Jiang XC, Francone OL, Bruce C et al. Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J. Clin. Invest. 98, 2373-2380 (1996).
   Google Scholar
• Van Lenten BJ, Wagner AC, Jung CL et al. Anti-inflammatory ApoA-I mimetic peptides bind oxidized lipids with much higher affinity than human ApoA-I. J. Lipid Res. 49, 2302-2311 (2008).
   Google Scholar
• Illuminating discussion on the pharmacodynamics of mimetic peptides and what they delineate about oxidatively damaged lipoproteins.
   Google Scholar
• Navab M, Anantharamaiah GM, Reddy ST et al. Apolipoprotein A-I mimetic peptides. Arterioscler. Thromb. Vasc. Biol. 25, 1325-1331 (2005).
   Google Scholar
• Watson C, Weissbach N, Kjems L et al.Treatment of patients with cardiovascular disease with L-4F, an Apo-A1 mimetic, did not improve select biomarkers of HDL function. J. Lipid Res. 52, 361-363 (2011).
   Google Scholar
• Discussion about a different isomer of the much-studied D-4F ApoA1 mimetic peptide.
   Google Scholar
• Ansell BJ, Navab M, Hama S et al. Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108, 2751-2756 (2003).
   Google Scholar